ClinicalTrials.gg
CompletedNCT04184466Updated Dec 3, 2019

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects

An interventional study of Insulin Aspart and NovoRapid® Penfill® in Clamp Study, sponsored by Geropharm. Completed at 2 sites in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by Geropharm · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2018, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Pharmacokinetics and pharmacodynamics study of 2 formulations of insulin aspart (Insulin Aspart GEROPHARM vers. NovoRapid® Penfill® Novo Nordisk)

Read the detailed description

A randomized double blinded two-way crossover single-dose pharmacokinetics and pharmacodynamics study of Insulin Aspart (LLC "GEROPHARM", Russia) versus NovoRapid® Penfill® (Novo Nordisk) in normal healthy subjects using the euglycemic clamp technique

02

Conditions studied

  • Clamp Study

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • Insulin Aspart
03

In context

Lead sponsor

Geropharm is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical, laboratory, and instrumental examination methods.
  3. Age of 18-45 (both incl.).
  4. equal to 18.5-30.0 kg/m2, body weight equal to 55.0-100.0 kg (both incl.).
  5. Volunteers' consent to all restrictions imposed during the study, including adequate methods of .
  6. Russian citizenship.

Exclusion criteria

Exclusion Criteria:

  1. Weighed allergic anamnesis.
  2. Increased sensitivity in the history of heparin, insulin or any of the of the study drugs.
  3. Any acute and chronic diseases, incl.:

    1. of the cardiovascular system, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.
    2. positive tests: (Ag), (Ab), (Ab), syphilis (Ab).
  4. 10% deviation from references in lab tests.
  5. Abnormalities of the and deviations in basic vital signs from the norms (screening).
  6. Episodes of hypoglycemia in the anamnesis; the presence in the family history of cases of a verified diagnosis of diabetes mellitus in the immediate family.
  7. Fasting plasma glucose> 6.1 mmol / L.
  8. > 6% (screening).
  9. Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after loading with glucose).
  10. Deep vein thrombosis of lower extremities in a history of life or in a family history.
  11. Any diet (vegetarian, etc.) extreme physical exercise, night shift work.
  12. Taking medications, phytopreparations, biologically active supplements less than 14 days before screening.
  13. History of significant drugs abuse conditions for 3 years prior to screening.
  14. Significant blood loss less than 3 months before the screening.
  15. Recovery after surgery process; scheduled surgery.
  16. Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol, including psychiatric disorders.
  17. A positive test for the content of drugs in the urine (screening)
  18. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism.
  19. Positive test for alcohol content in the exhaled air.
  20. Nicotine dependence (use of tobacco less than 6 months before the start of screening).
  21. Presence of oncology disease in the anamnesis 5 years prior the start of screening.
  22. Participation in a clinical trial of any medications less than 3 months or 5 half-lives before the IP administration.
  23. Any conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Insulin Aspart

    Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg

    Drug: Insulin Aspart

  • Active comparator
    NovoRapid® Penfill®

    Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg

    Drug: NovoRapid® Penfill®

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-t)

    Pharmacokinetics of insulin aspart by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))

    Time frame: -60, -30, 0 minutes (pre-dose) and 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 135, 150, 165, 240, 300, 360, 420 and 480 minutes post-dose

  2. Cmax

    Pharmacokinetics of insulin aspart by Assessment of Observed Maximum Plasma Concentration (Cmax)

    Time frame: -60, -30, 0 minutes (pre-dose) and 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 135, 150, 165, 240, 300, 360, 420 and 480 minutes post-dose

07

Study locations

2 sites
  • Endocrinology Research Centre
    Moscow, 117036, Russian Federation
  • Almazov National Medical Research Centre
    Saint Petersburg,, 197341, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Dec 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2019
First posted
Dec 3, 2019
StartActual
Oct 18, 2018
Primary completionActual
Dec 19, 2018
CompletionActual
Dec 19, 2018
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04184466
Lead sponsor
Geropharm
Responsible party
Sponsor
First posted
Dec 3, 2019
Start date
Oct 18, 2018
Primary completion
Dec 19, 2018
Completion
Dec 19, 2018
Last update
Dec 3, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion